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Abstract: Nanoparticles are particles that range in size from about 1–1000 nanometers in diameter,
about one thousand times smaller than the average cell in a human body. Their small size, flexible
fabrication, and high surface-area-to-volume ratio make them ideal systems for drug delivery.
Nanoparticles can be made from a variety of materials including metals, polysaccharides, and
proteins. Biological protein-based nanoparticles such as silk, keratin, collagen, elastin, corn zein,
and soy protein-based nanoparticles are advantageous in having biodegradability, bioavailability,
and relatively low cost. Many protein nanoparticles are easy to process and can be modified to
achieve desired specifications such as size, morphology, and weight. Protein nanoparticles are
used in a variety of settings and are replacing many materials that are not biocompatible and have
a negative impact on the environment. Here we attempt to review the literature pertaining to
protein-based nanoparticles with a focus on their application in drug delivery and biomedical fields.
Additional detail on governing nanoparticle parameters, specific protein nanoparticle applications,
and fabrication methods are also provided.
Keywords: protein; nanoparticles; biomaterials fabrication; nanomedicine; bioimaging; drug delivery
1. Introduction
Drug delivery systems are a valuable means of disease treatment and prevention in today’s
medicine. Prior to the introduction of drug particle microencapsulation in the 1950s, drug delivery
was based on rudimentary practices such as applying poultices or consuming herbal ingredients [1].
These methods, while moderately effective at the time, are inefficient and pose unnecessary health
risks. However, progress in the understanding of pharmacokinetics has led to the development of
sophisticated and novel methods for administering a variety of therapeutics throughout the body.
Now, drug delivery methods allow for controllable drug-release and targeting to improve the safety and
efficacy of treatment. To further enhance drug delivery, nanotechnology has begun to be implemented
in the field. Specifically, the use of nanoparticles as carriers is an effective strategy to deploy medications
to specifically targeted parts of the body [2,3].
Nanoparticles, or microspheres, are ideal drug delivery systems for both controlled and targeted
drug delivery. Their sizes typically range between 1–100 nanometers in diameter and can extend to
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more than 1000 nanometers. However, particle sizes smaller than 200 nm are more preferable for use in
nanomedicine due to their ability to traverse micro-capillaries [4]. There are several aspects to consider,
such as size and surface charge as examples, before selecting an appropriate nanoparticle material [5,6].
While nanoparticles can be fabricated from synthetic materials, protein-based nanoparticles have
received considerable more attention due to their biodegradability and tunable properties [6,7].
Advances in medical technology have also brought about techniques to synthesize protein-based
materials that offer improved efficacy and reduced costs compared to synthetic materials [8].
Protein polymers are natural macromolecules derived from plants and animals which makes
them an easily obtainable, renewable resource. In addition to their biodegradability and tunable
properties, nanoparticles fabricated from protein-based materials are often biocompatible and can be
easily processed [9,10]. There are a variety of different protein polymers suitable for nanoparticle-based
drug delivery each with their own unique structure-function relationships. In this review, the structure
and property relationships of these natural protein-based polymers will be discussed, as well as their
methods of preparation. The use of these nanoparticles in medicine will then be reviewed with a focus
on their application for nanoparticle-based drug delivery.
2. Categories of Protein Materials
Due to the wide range of applications for protein nanoparticles, there are many types of proteins
that are used to create protein nanoparticles. The type of protein polymer required may vary depending
on the application. In this review, silk fibroin [11], keratin [12], collagen [13], gelatin [14], elastin [15], corn
zein [16], and soy protein [17] will be given particular attention due to their popularity in biomaterials
research (Figure 1). However, additional protein polymers such as casein [18], fibrinogen [18],
hemoglobin [19], bovine serum albumin [20], gluten [20] have also been used to create nanoparticles.
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2.1. Silk Fibroin
Silk fibroin protein is among the most popular natural polymers used for the creation of
biomaterials due to its acceptance by the US Food and Drug Administration (FDA), low cost,
and abundance. Commonly extracted from silk produced by the Bombyx mori silkworm, fibroin
can be easily isolated after removal of the external sericin protein coating through treatment with
sodium carbonate. The resulting fibroin protein is made of semi-crystalline structures comprised of
a light and heavy chain [21]. An isoelectric point (IEP) below pH 7 and molecular weight of 83 kDa
have been reported for regenerated silk fibroin, but the latter value may vary depending on the
extraction procedure and duration of treatment [22,23]. The repetition of amino acids in the pattern
(Gly-Ser-Gly-Ala-Gly-Ala)n leads to crystalline beta-sheets that are then stacked in an antiparallel
configuration [24–26]. This structure gives silk fibroin robust mechanical properties and high tensile
strength. The crystallinity and conformation of silk fibroin can also be modulated to allow for high
encapsulation of drugs while preserving their pharmaceutical activity [27].
Silk-based nanoparticles have proven effective in the delivery of both hydrophobic and
hydrophilic drugs such as indomethacin and aspirin [28] of varying molecular weights, as well as
anti-cancer therapeutics such as doxorubicin [11], bioactive molecules including growth factors VEGF
((vascular endothelial growth factor) and BMP-2 (bone morphogenetic protein 2) and Horseradish
peroxidase and glucose oxidase enzymes [29], as well as plasmid DNA [30]. Silk-composite
nanoparticles have also been fabricated by combining the protein with other biopolymers such as
insulin [31], chitosan [32], and albumin [33] and synthetic polymers such as polyvinyl alcohol [34],
polylactic acid [35], and polycaprolactone [36]. These approaches allow for a greater degree of tunability
that can potentially increase the efficacy of drug delivery.
2.2. Keratin
The use of keratin as a biomaterial has been rapidly expanding over the past 40 years because
of its abundance, low cost, biocompatibility, and its ability to biodegrade safely [37]. Keratin is a
fibrous structural protein with molecular weight of up to 63 kDa and IEP between pH 4.5 and 5 that is
derived from the human or animal epidermis and epidermal appendages, such as hair, scales, feathers,
and quills in mammals, reptiles, and birds [38–40]. The keratin protein is most commonly found in
epithelial cells. It is a structural protein that provides the framework for cell-cell adhesion to form
a protective layer. Keratin structure is a left-handed alpha-helix which can be coiled together with
other keratin proteins to form a polymerized complex. There are three different forms of keratin: α-,
β-, and γ-keratins. α-keratins contain intermediate filaments, which are involved in the cytoskeleton,
and are mainly found in soft tissues. β-keratins also contain intermediate filaments, but are found
in hard tissues, such as scales and nails. γ-keratin is not involved in the structural elements of the
cytoskeleton [37].
According to recent studies, keratin-based nanoparticles are effective anticancer drug carriers
possessing a degree of tumor targeting ability and controlled drug release [12,41]. Disulfide bonds
from cysteine residues and hydrogen bonds from amine groups grant keratin nanoparticles the
durability to deliver drugs with high molecular weight to their target location. In addition, keratin
is negatively charged allowing positively charged molecules to better adhere to the nanoparticle for
more effective transport. The targeting ability of keratin-based nanoparticles is attributed to their pH
sensitivity [12,41–43]. Keratin-based nanoparticles can respond to changes in pH to release their drug
contents accordingly in a controlled release. Due to its intrinsic water stability, keratin is also a desirable
support polymer for synthetic nanoparticle composites [43]. Silver nanoparticles coated with keratin
are shown to have improved stability in aqueous environments [44]. Keratin is also advantageous
for supporting cell adhesion and promoting cellular proliferation [41,45]. Gold nanoparticles coated
with keratin are shown to exhibit biocompatibility with improved antibacterial activity [46]. Keratin
appears to be an ideal drug carrier which should be investigated further for drug delivery purposes.
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2.3. Collagen and Gelatin
Collagen is the most abundant biopolymer in the human body [47]. This fibrous protein is a major
component of the extracellular matrix and is responsible for maintaining its structure. The majority of
collagen is located in connective tissues such as the skin, tendons, and ligaments [48]. Collagen can be
divided into two different groups: non-fibrillar and fibrillar, which can be further divided depending
on the structure and use. Type 1 of fibrillar collagen is the most common type found in the human
body and has a molecular weight in the 100 kDa range. Long, triple helical structures are responsible
for strength and flexibility in collagen. This helical structure has high mechanical strength due to a
repeating amino acid sequence Gly-X-Y, where “X” and “Y” are commonly proline, hydroxyproline,
leucine, or lysine. The individual helical structures, known as tropocollagens, will bind together and
form a fibril structure. These fibril structures can then be cross linked together to form suitable cell
scaffolds for use in tissue engineering [49].
Due to collagen’s biocompatibility and low antigenicity, collagen-based nanoparticles have been
used for the delivery of pharmaceuticals such as theophylline, retinol, tretinoin, and lidocaine [13,50,51].
Collagen is capable of resembling the microenvironment of some tumors allowing collagen nanoparticles
to effectively infiltrate the areas and deliver anticancer therapeutics [52]. Physical properties of collagen
nanoparticles such as size, surface area, and absorption capacity, are easy to configure [53]. This makes
collagen nanoparticles a prime candidate for controlled drug release strategies.
In comparison, gelatin is a biopolymer derived primarily from insoluble Type I collagen through
thermal denaturation or disintegration [54]. Like collagen, gelatin has received much attention in
the biomedical field due to its biocompatibility and high abundance. Gelatin contains a triple helical
structure, similar to collagen, made of repeating amino acids: alanine, glycine, and proline [55].
Depending on the production process, gelatin can be classified as type A or type B and consist of
varying molecular weights. Type A gelatin is extracted through an acidic process, while type B
is process under alkaline conditions [56]. Type A gelatin is positively charged and has an IEP of
approximately pH 9. Conversely, type B gelatin is negatively charged and has an IEP of pH 5 [56].
Tissue engineering scaffolds have thus been made from gelatin as well. Alternatively, gelatin can also
be formed into a gel which can be used in the place of thermoplastic polymers [57].
Gelatin is also a favorable nanoparticle material due to its relatively low antigenicity and
non-carcinogenic nature [14,58]. Gelatin nanoparticles are extensively used as successful anticancer
drug carriers [59] and gene delivery vehicles [60]. Gelatin nanoparticles are able to deliver drugs
across the blood brain barrier, which is a semipermeable barrier that is highly studied for drug
delivery systems [55]. Gelatin nanoparticles have also safely and efficiently carried NS2, a recombinant
gene from the hepatitis C virus, without negatively impacting the function of the gene [61].
In addition, gelatin can be blended with other natural polymers to enhance their therapeutic behavior.
An alginate-gelatin composite nanoparticle benefitted from an electrostatic bond formed between the
two polymers and allowed for a more controlled release of the encapsulated drug, doxorubicin [62].
Utilizing gelatin is both a promising and convenient approach for nanoparticle-based delivery of genes,
vaccines, and drugs.
2.4. Elastin
Elastin is an important protein found in elastic fibers, specifically in the extracellular matrix.
It provides support and elasticity to many structures such as the heart, lungs, skin, and blood vessels
with high molecular weight species weighing 130 to 140 kDa [63]. It is insoluble and therefore can retain
its shape and insolubility after stretching [8]. However, insoluble proteins are often not biocompatible
and are difficult to alter. Through the use of recombinant proteins and peptide synthesis, soluble
proteins that have elastin-like properties called elastin-like-peptides (ELP) are able to be produced with
tunable molecular weights [64]. These polypeptides are derived from tropoelastin, the building block
of elastin. This precursor molecule is vital in the exploitation of ELP’s. ELP’s are able to react to stimuli
due to their temperature sensitivity, which induces a phase transition [65]. They can then self-assemble
Int. J. Mol. Sci. 2018, 19, 1717 5 of 20
by the process of coacervation into a more ordered structure such as beta-spiral structure [66]. This
property, along with their biocompatibility, makes them excellent prospects for biomedical applications.
Elastin-based proteins also have the ability to communicate with cells through naturally occurring
cellular receptors such as elastin binding protein (EBP) [67]. This receptor can be exploited by using
tropoelastin-based polymers to induce or inhibit various cell functions [66].
Elastin, or ELP, nanoparticles have proven effective in delivery of cytokines such as BMP-2 and
-14 [68], anticancer therapeutics such as doxorubicin [69], and genes [70]. Their ability to self-assembly
when exposed to certain temperatures serves as a mechanism to entrap active substances [15] and
achieve controlled drug release [69]. The polymer functionality of ELP nanoparticles can be controlled
by using a recombinant fabrication technique [69,70]. This means that variables pertaining to drug
release, such as composition and molecular weight, can be tailored for a variety of applications in
drug delivery.
2.5. Corn Zein
Zein is low molecular weight protein (20 kDa), found within the cytoplasm of corn cell endosperm
and is insoluble in water except in the presence of alcohol, urea, alkali, and anionic detergents [71].
The protein has an IEP of pH 6.2 and is a mixture of two different peptides: α zein and β zein [72].
α zein is the most widely used variety due to its abundance [73,74]. Zein has a helical wheel shaped
structure with nine homologous units arranged in a non-parallel way with hydrogen bonds stabilizing
it. This helical shape gives zein a globular structure similar to insulin and ribonuclease [73]. Zein can be
extracted using primary, secondary, and ternary solvents. Primary solvents consist of a compound that
dissolves zein in a concentration greater than 10%. Secondary solvents are organic compounds. Ternary
solvents are a combination of solvent, water, and alcohol. Zein is commonly used in fibers, adhesives,
plastics, ink, chewing gum, and as a preservative coating for some food and pharmaceuticals [74].
Zein nanoparticles are successful drug carriers for encapsulation and controlled release of fat
soluble compounds such as α-tocopherol [75–77], other proteins [16], vaccines [16,78], and vitamins
such as D3 [79,80]. Due to the protein’s hydrophobicity, zein nanoparticles are promising oral drug
delivery vehicles able to protect encapsulated contents from harsh acidic environments such as in
stomach acid [79]. Zein nanoparticles can also have their properties improved by combining the
natural polymer with other substances. For example, sodium caseinate was incorporated with zein
nanoparticles to improve particle stability in water [81]. Zein nanoparticles are an attractive drug
delivery system due to their high stability in a variety of environments and tunable properties in
combination with certain molecules.
2.6. Soy
Soy protein is a globular protein isolated from soybeans, known as soy protein isolate, and is
one of the most abundant types of plant proteins. The globular structure is comprised of two major
subunits, conglycinin and glycinin, which contain all amino acids particularly glutamate, aspartate,
and leucine [82]. This structure composition gives soy protein relative stability for long storage life [83]
and biocompatibility [84]. When the globular protein is treated with enzymes, soy protein hydrolysates
below 1 kDa and between 1 and 5 kDa can be obtained and further processed [85]. In addition, soy
protein is biodegradable as it can be digested if consumed. For example, soy protein-based edible films
are often used as a wax coating for fruits to preserve their quality [86–88]. Soy protein films, scaffolds,
and hydrogels have also been applied in tissue engineering for wound healing and transdermal
drug delivery [89]. With every amino acid available, soy protein is effective in supporting cellular
communication and cell proliferation. The amino acid composition may also attribute to soy protein
being used as protection against bacterial infection [83,90].
Soy protein nanoparticles are becoming more popular due to the high abundance and low cost of
the protein, as well as its biodegradability and low immunogenicity. The amino acid composition gives
soy protein nanoparticles an advantage in encapsulation of highly hydrophobic drugs [17]. Unlike
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zein, soy protein nanoparticles are soluble in aqueous environments which can be used in different
oral drug delivery scenarios. Soy protein isolates are used as a coating in conjunction with other
materials either for protection [91] or for physical or chemical surface modification [17,92]. For example,
magnetic nanoparticles prepared with soy protein isolate benefit from enhanced functional surface area
increasing the loading of enzymes [92]. The protein coating also offers a degree of bioinert behavior to
otherwise non-immunogenic nanoparticle materials.
2.7. Other Proteins: Casein, Fibrinogen, Hemoglobin, Bovine Serum Albumin, Gluten
Along with the many proteins mentioned above, there are some that will be excluded from this
review but are worth mentioning. Casein, fibrinogen, hemoglobin, bovine serum albumin, and gluten
are just a few of many. Similar to those previously explained, the use of these proteins depends on
their properties and the application’s demands. Casein is very useful in hydrophilic environments
since casein is a hydrophilic protein in itself. It is useful for water-based environments since as a
microsphere they disperse instead of aggregate [18]. As a micro-/nanosphere, fibrinogen polymerizes
when used in conjunction with a serine protease and forms a protein mesh that can be used to cover
and treat open wounds or used in vitro for more in depth biomedical applications [93]. Hemoglobin
as a micro-/nanoparticle can be used as an oxygen deposit to make oxygen releasing biomaterials [19].
Bovine serum albumin can be used to pack prepared protein particles to aid in protein and drug
delivery [94]. Gluten as a microsphere can be used as a drug delivery vehicle that is very effective
compared to other widely used proteins [20]. While these proteins are not described in further detail in
this review, each protein possesses their own unique advantages when applied in nanoparticle-based
drug delivery.
3. Fabrication Methods
Due to the necessity of obtaining particles of different sizes, shapes and weights, there are many
fabrication methods that are available for the creation of nanoparticles. Fabrication methods will also
vary depending on the properties of the individual polymers, such as temperature dependence.
Fabrication methods that will be discussed in this review include pH variation, spray-drying,
phase separation, milling, rapid laminar jet, and polymer chain collapse. The synthesis of blended
protein-based nanoparticles will also be discussed. The advantages and disadvantages of these
fabrication methods are summarized in Table 1.
Table 1. Advantages and disadvantaged of the common protein-based nanoparticle fabrication methods.
Method Advantages Disadvantages
pH Variation [95]
• Control for particle size
• Control secondary structure of protein
• Control for zeta potential
• Produces chemically and physically stable
particles Experimentally simple
• Post-fabrication drug loading is required




• Easily encapsulate hydrophilic drugs
• Useful for heat-sensitive samples
• Control for particle size
• Limited to small scale production
• Challenging to incorporate hydrophobic drugs
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Table 1. Cont.
Method Advantages Disadvantages
Rapid Laminar Jet [97]
• Control for particle size
• Production of uniform particles
• Production of strong, stable particles
• Possibility of coalescence
• Many parameters must be controlled for
Phase Separation [98]
• Specialized equipment is not required
• Particle size can be controlled by adjusting
protein concentration
• Uniform particles are produced
• Particle sizes are limited to 50–500 nm in diameter
• Organic solvents are required
• Limited to small scale production
Milling [99]
• Cost effective
• Large scale production is possible
• Control of nanoparticle size
• Experimentally simple
• Heat is released during the process requiring
chamber to be cooled
• Little control over nanoparticle shape
• Nanoparticles must be coarse
Polymer Chain
Collapse [100]
• Properties of the nanoparticle can be easily
controlled by selection of the
precursor chain
• Production of particles with high stability
• Particles with improved spherical shape
are produced
• Particle size is limited to 5–20 nm in diameter
• Side reaction may be difficult to control
3.1. pH Variation
The drug delivery properties of silk fibroin can be modified by changing many factors during
nanoparticle synthesis. One of these factors is the pH of the silk fibroin [95]. Particles are made by
salting out a fibroin solution with potassium phosphate. The pH of the particles can be controlled
depending on what type of potassium phosphate is used in the salting out. Mono potassium phosphate
has a pH of 4 and dibasic potassium phosphate has a pH of 9. Silk fibroin particles with a pH of
4 develop silk II rich secondary structures while silk fibroin particles with a pH of 9 developed a silk I
rich secondary structure. Particles with the silk II structure or the lower pH are less chemically stable
than the particles with a higher pH and the silk I structure. When a positively charged drug is loaded
into a negatively charged silk fibroin particle there is a difference in the release depending on the pH of
the particle. Particle with the silk II structure and low pH have an increased initial release, whereas the
high pH particles have a low release. However, particles at a neutral pH of 7 had an overall increased
release over the entire time not just initially.
3.2. Spray-Drying
Spray-drying is a technique that is used to fabricate nanoparticles from a liquid sample. The liquid
sample is sprayed out of a nozzle into a chamber where heated nitrogen and carbon dioxide gas flow
in the direction of the spray (Figure 2). In the bottom of the chamber, there are electrodes which are
used to collect the nanoparticles. As the sprayed droplets move towards the bottom of the chamber,
they become electrostatically charged due to these electrodes. This is a one-step process that is a quick,
cost effective method for small scale protein particle production. One application of spray-drying is
for use in drug delivery systems due to the ability of hydrophilic drugs to be encapsulated in these
spray-dried nanoparticles [96]. This nanoparticle fabrication technique is useful for samples that
are heat-sensitive since the solvent evaporation helps maintain the temperature of the nanoparticle
droplets. This method of nanoparticle synthesis also gives the user the ability to control the size of the
particle that is produced by changing parameters, such as the size of the nozzle and speed at which
they are sprayed out [101].
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is sprayed alongside of heated gas in a chamber that leads to electrodes which are used to collect
the charged sprayed nanoparticles. (Reproduced with permission from [102], Copyright Springer
Nature, 2015).
3.3. Rapid Laminar Jet
Particles can be also made using a rapid laminar jet method. The feed liquid will contain a certain
number of compounds from which the particle can be made. Spherical drops form when a liquid jet
discharges from a small opening at laminar flow conditions. This formation behavior of the drops
is resulted because of t e surface energy and tension of the jet. The liquid spheres will be dispersed
in some type of fluid or ga /air depending on the mechanis . Drop size is-based on the length of
the jet. For best results t jet length between breakp ints should be five times the diam ter f the
stream which gives particle sizes of about twice that of the jet. This laminar breakup of the jet is a
result of small disturbances. These disturbances must be controlled to preserve uniformity in drop
sizes. To control these disturbances a controlled uniform vibration is applied to the jet. Ideally the
frequency of the vibration is close to the naturally occurring frequency for laminar breakup. This leads
to a clean controlled breakup and uniform drop sizes [97].
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3.4. Phase Separation
Out of the various methods of protein nanoparticle fabrication, emulsion-solvent evaporation
is the most popular. This technique was the first to form polymer nanoparticles [103]. Organic and
aqueous phase separations are the backbone of this method. Prepared polymers are placed in
an organic solvent. A surfactant is added to the aqueous phase in order to prevent the fusion of
emulsion particles [104]. The solution is then subjected to a mixing method such as ultrasonification.
Mini-emulsion droplets of polymer are formed. Finally, the solvent is separated. This is often completed
by evaporation of the organic phase. The remaining solution contains polymer nanoparticles which
can be collected through a centrifuge. This method produces particles in the 50–500 nm size range.
Particle size could be controlled by altering the concentration of polymer solution [105]. This technique
is extremely popular due to the availability of conjugated polymers [98].
Another method based on separations is the coacervation method. This is commonly referred to
simply as phase separation but for the purposes of this paper it is included in this section. This method
requires the separation of two liquid solutions. One will contain the protein polymer and the other is a
solvent. Through some means of disrupting equilibrium such as the addition of a salt, coacervation is
induced. The charges create electrostatic forces which induce the formation of nanoparticles [98].
3.5. Milling
Milling is a fabrication technique for nanoparticles that requires mechanical energy to break down
larger particles into fine nanoparticles (Figure 3). This fabrication technique is commonly used for
nanoparticles that are to be used in drug delivery [106]. Milling is a cost-effective way to produce
nanoparticles in a large-scale production. High energy ball milling involves the subjection of coarse
nanoparticles to high energy collisions from the milling balls. Coarse nanoparticle powder is placed in
a chamber that contains milling balls and mechanical movement is applied to the cylindrical chamber
to accelerate the milling balls which can roll over and collide with the powder. These collisions and
other mechanical force from the milling balls causes the coarse nanoparticles to break down into fine
nanoparticles. The chamber must be cooled due to the heat energy released from the mechanical
energy exerted on the nanoparticles. This fabrication technique allows the user of the system to control
the size of the nanoparticles by altering the speed of the rotation of the cylindrical chamber [99].
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Figure 3. This figure shows the basic mechanism used in high energy ball milling. As the cylinder
rotates, the milling balls are accelerated and through physical force fracture the polymer material that
is placed in the chamber.
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3.6. Polymer Chain Collapse
Single-chain collapse of polymers is a method to produce individual single-chain polymer
nanoparticles (SCNP). This method can produce particles in the range of 5–20 nanometers. In addition,
intrachain folding produces particles that have great stability compared to other techniques [100].
Control of the precursor chain can also dictate the properties of the nanoparticle, allowing for the
production of distinct molecules [107].
There are different varieties of the SCNP method and the type of reaction is dependent on the
functional groups involved. However, all the methods benefit more from intramolecular cross-linking
rather than intermolecular cross-linking [108]. Homofunctional chain-collapse involves placing a
functional group that is likely to bind with itself on the precursor chain and then performing a reaction
that couples the functional group [107]. This method often produces particles that are not globular
in shape. Instead, heterofunctional coupling is being looked to for improved results. This requires
two functional groups which are orthogonally cross-linked. There are many ways to perform the
cross-linking in both hetero and homofunctional chain collapses. Data has shown that this method
produces nanoparticles with improved spherical shape [109].
3.7. Protein Particle Composite
Protein particle composites contain more than one protein or polymer, the addition of which can
be used to tune the mechanical and physical properties of a drug delivery vehicle. The method in
which they are fabricated depends on the type of particle desired and the differing properties of the
additional component. The properties can be a variety of different things such as mechanical properties,
electric properties, electromagnetic properties, elasticity, crystallinity, moldability, and many more.
When choosing the different type of additional polymer to add, it usually contains an additional
characteristic that the main protein does not. Where one protein’s structure may be dependent on pH,
adding another material to form a stable complex between the two to withstand a lower pH could
make more fabrication methods possible.
For fabrication of these particles, it depends what end product is desired. Any previous or
following fabrication method that is described can be used to make composite protein-based particle.
The only difference between this method and the others is the fact that a protein composite must be
made before or after fabrication. For example, if the particles are going to be fabricated using spray
drying, a liquid protein mixture can be made before spray drying is done or individual nanoparticles
can be formed and then mixed together to create the same product. If a certain percentage of protein
is desired in the final product, it is important that an appropriate fabrication method is selected.
Fabrication methods can affect the resulting nature of the particle. Particle behavior depends on their
surface composition, geometry, and size among other characteristics. There are many more methods
that can be utilized for fabricating protein particles apart from what was described in this review [110].
4. Factors to Control Particle Formation
In nanoparticle formation there are many factors that can be controlled to modify drug delivery,
such as size, molecular weight, and shape. These factors are mainly determined by the fabrication
technique applied but can also be due to the properties of the polymers themselves.
4.1. Size
Nanoparticle size can vary depending on the molecular weight of the protein polymer used.
Typically, nanoparticle size ranges from 1–100 nanometers but they can extend to 1000 nanometers in
diameter [111]. One way to control nanoparticle size is to prevent aggregation of the nanoparticles,
which can be done by introducing chemicals that help prevent this aggregation by reducing disulfide
bonds or by altering the charge state of the polymers [112]. Other factors related to controlling the size
of the nanoparticles vary by the technique used to produce them. With the spray drying nanoparticle
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manufacturing technique, the size of the particles can be altered by changing the size of the nozzle
used to spray the polymeric nanoparticle solution into the drying chamber; the size can also be altered
by the speed at which the solution is sprayed [101].
4.2. Shape
There are many different forms of nanoparticles. The two fundamental types are nanospheres and
nanocapsules. The main difference between these types are that nanospheres contain a polymer matrix
inside, whereas nanocapsules have a shell that separates the encapsulated polymer from the outside
environment (Figure 4). Solid lipid nanospheres are being studied as potential drug carriers due to their
matrix morphology. This allows for controlled release and protection of the drug [113]. These particles
can be formed by subjecting alkyl cyanoacrylates to polymerization in emulsion [114]. An additional
method is precipitating polymers that have already been altered [113]. Solid nanospheres may also
be formed using microfluidics method. This method is extremely cost efficient and allows for more
control of particle features. The solvent volatility can be altered to shape the surface. Variances in flow
rate and the architecture of the devices can create different geometries [114].
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Nanocapsules are somewhat the opposite of solid nanoparticles. This is based on their hydrophobic
and hydrophilic interactions. The counter methods can be applied to form nanocapsules. Adding an
oil to the emulsion polymerization results in a core-shell formation [113]. Essentially, the presence
or absence of oil dictates which type of nanoparticle will form. Another type of nanoparticle is the
Janus nanoparticle. These particles consist of two different sides, each with their own properties.
These properties can include hydrophobicity and hydrophilicity. The combination of functionalities
allows for stimuli response and unique assemblies. Janus particles can be formed by masking. This
process involves protecting one region f the particle while the other is functionalized. The mask is
then emoved, and the final product is particle with a dual nature particle [115]. Another pr cess
is self-as embly. Fir t block copolymers undergo phase separation. Th n pe ific cross-linking must
occur, followed by disassembly of larger structures [116].
4.3. Properties of the Protein
When designing a rotein-based nanoparticle, it is imp rtant o consid r how th protein will
interact with the en apsulated drug and physiological environment. Ult mately, a tein with the
appropriate molecular weight and IEP must be chosen. The molecular weight of the protein used to
create the nanoparticle is important to consider since it can affect how much drug can be effectively
stored and the particle targeting mechanism in the body. In some instances, a nanoparticle made from
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a very high or low molecular weight protein can result in lower encapsulation efficiency. A moderate
molecular weight protein is often more appropriate and can help to achieve higher encapsulation
efficiency [117]. The molecular weight can also contribute to the pathing of the nanoparticle through the
body. In addition to molecular weight, the IEP of the protein will affect the stability of the nanoparticle
in different environments. At pH near the IEP, nanoparticles may begin to aggregate and decrease
in stability [118]. This can inhibit their circulation throughout the body as well as their drug release.
Therefore, a protein with the appropriate IEP and molecular weight must be chosen to ensure that
nanoparticles withstand certain environments.
5. Novel Applications of Protein-Based Nanoparticles
Protein nanoparticles offer a wide range of uses in medicine as both drug delivery vehicles and
bioimaging aids.
5.1. Bioimaging
Polymer nanoparticles are gaining traction as contenders to replace typical fluorescent dyes.
These are used in non-specific and targeted microscopic imaging [119]. In non-specific imaging, these
nanoparticles can be used to dye cells. Data demonstrates that phospholipid encapsulated polymer
nanoparticles are successful in providing quality fluorescent imaging of cancer cells. These cells
displayed no symptoms of toxicity. In addition, it is possible to tune the wavelength emitted by
altering the conjugated protein polymer [120]. These properties, along with an increased circulation
period, could lead to applications in vivo. In addition, protein nanoparticles have a bright future in
targeted cellular imaging. These particles have an increased uptake due to the enhanced permeability
and retention of advanced tumors. Near IR light can provide excellent imaging quality when paired
with a polymer nanoparticle-based probe due to the previously mentioned properties [121]. Overall,
the applications of these particles in the biomedical imaging field are rapidly growing.
To enhance the biocompatibility and cellular uptake of nanodiamonds (ND), Khalid et al.
encapsulated the material in silk fibroin nanospheres using a co-flow technique. Due to silk fibroin’s
transparency and low background signal, the photoluminescence of the NDs was not diminished.
In fact, NDs encapsulated in silk fibroin spheres fluoresced 2–4 times brighter than NDs alone. The 400
to 600 nm spheres were also found to be highly stabile in an aqueous environment, but began to degrade
after one week of incubation at 37 ◦C. When introduced to fibroblast cells in vitro, the intracellular
mobility and diffusion of NDs was improved [122]. Li et al. also used silk fibroin to create nanoparticles
for bioimaging, through hydrothermal treatment that simply involved heating the protein at 200 ◦C
for 72 h. This procedure produced water-soluble, nitrogen-doped, photoluminescent-polymer-like
carbonaceous nanospheres (CNSs) that measured approximately 70 nm in diameter and could easily be
isolated through filtration. These nanoparticles exhibited low cytotoxicity when incubated with HeLa
cells and fluoresced in the perinuclear regions once ingested. CNSs could also be used to image tissue
at a depth of 60 to 120 µm with no blinking and low photobleaching [123]. These studies illustrate the
improvements that may result from the incorporation of protein into nanoparticles for bioimaging.
In addition to silk fibroin, gelatin nanoparticles have also been utilized as bioimaging platforms.
Liu et al. created gelatin nanocapsules containing gold nanoparticles by denaturing gelatin
polypeptides that then absorbed onto citrate-stabilized gold nanoparticles. A thin layer of silica
was then used to stabilize these particles that measured approximately 50 nm in diameter and hold
promise in Raman-active bioimaging [124]. Gelatin has also been used to coat Cadmium telluride
(CdTe) quantum dots (QDs), leading to an improvement in their cytotoxicity and biocompatibility.
In this study, Byrne et al. introduced gelatin single- or multi-stranded polypeptides during QD
synthesis, to control their growth and nucleation. Functional groups present in the glycine, proline,
and 4-hydroxy proline residues of gelatin were then able to interact with the surface of the CdTe QDs,
allowing for their coating. When incubated with macrophages, these “jelly dots” were successfully
engulfed by the cells, resulting in the illumination of their membranes. When compared to QDs alone,
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cells exposed to QDs treated with gelatin showed a lower lysosomal pH and cellular permeability,
suggesting decreased toxicity of the particles [125]. In both studies, the ability to further functionalize
the surface of these particles due to their natural polymer coating, may further enhance their efficacy
in bioimaging.
5.2. Drug Delivery Vehicle
Protein-based nanoparticles have also found new use as drug delivery vehicles. In addition
to their biocompatibility and biodegradability, the surface of protein nanoparticles can be easily
functionalized due to their defined primary structure, while charged proteins can facilitate drug
loading through electrostatic interactions [6,126]. Such particles can also often be fabricated under
mild, aqueous conditions, making them easier and safer to process than ones based on synthetic
polymers [95]. The use of natural proteins has also been shown to increase cell retention and reduce
the effects of toxic byproducts produced during degradation [127].
One such protein used to create nanoparticles for drug delivery is corn zein. Due to its hydrophobic
nature, this protein is especially suited for the prolonged, controlled release of pharmaceuticals. Lai et al.
noted this effect when they used the protein to create nanoparticles loaded with the chemotherapeutic
agent, 5-Fluorouracil (5-FU). These particles were synthesized using a standard phase separation
procedure and measured approximately 115 nm in diameter. The corn zein particles were able to
encapsulate 5-FU at an efficiency of up to 56.7% which was then released after an initial burst of
22.4%. When injected into mice, the nanoparticles remained in circulation for 24 h before localizing
to the liver due to their high molecular weight [127]. Corn zein nanoparticles have also been used
for the controlled release of vitamin D3 [80], therapeutic proteins such as catalase and superoxide
dismutase [128], and anti-diabetic drugs [126]. In the latter study, Xu et al. developed hollow zein-based
nanoparticles through a two-step procedure. This fabrication technique began with the mixing of
corn zein and sodium citrate ethanol-based solutions. The zein polymer than aggregated around the
sodium citrate crystals, resulting in the formation of particles with a sodium citrate core and zein shell.
To create hollow particles, the core-shell particles were added to water, leading to the dissolution of
the sodium citrate core. The resulting hollow nanoparticles measured less than 100 nm in diameter
and were able to encapsulate 30% more drug compared to solid zein particles. This drug was then
released in a more sustained, prolonged manner over 200 h. When incubated with 3T3 fibroblast cells,
the particles were also successfully internalized by cells without effecting their viability [126].
Other plant-based proteins such as soy protein have also been used to create nanoparticles for the
controlled release of nutrients and pharmaceuticals. Due to soy’s balanced composition of nonpolar
and polar residues, it can act as a versatile carrier by storing drugs with various functional groups.
Using a desolvation method and a glutaraldehyde crosslinker, particles measuring between 200 and
300 nm in diameter were fabricated and loaded with curcumin. Curcumin was then released with an
initial burst of over 50% within the first 1.5 h, but continued to be released in a more controlled manner
over the next 8 h [17]. Although cell studies were not conducted, the established biocompatibility of
soy suggests that the particles were act as suitable drug delivery vehicles [84].
Negatively charged proteins such as keratin have also been used to fabricate nanoparticles that
are able to incorporate drugs through electrostatic absorption. When prepared through ionic gelation,
keratin particles allowed for the long-term and controlled release of the model drug chlorhexidine
(CHX). This fabrication technique involved the dropwise addition of a CHX solution to one containing
keratin. Negatively charged carboxylate groups on the outside of keratin aggregates attracted the
drug, allowing for its retention. CHX was then gradually released over 140 h in a pH-sensitive manner,
with greater release occurring at acidic and neutral pH [12]. Cheng et al. also created keratin-based
nanoparticles consisting of varying ratios of the oxidized (keratose or KOS) and reduced (kerateine
or KTN) forms of the protein. These particles were created using an ultrasonic dispersion technique
and measured between 345 and 400 nm, with decreasing diameter upon the addition of more KOS.
The addition of KOS also resulted in an increased release rate of the model drug, Amoxicillin (AMO).
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The nanoparticles were found to be mucoadhesive due to the electrostatic interaction and disulfide
bonding between gastric mucin and KTN, and hydrogen binding with KOS. These results suggest that
keratin-based nanoparticles may be an ideal carrier for mucoadhesive drug delivery [42].
6. Conclusions
Protein polymer and protein composite materials are becoming more accepted in the realm of
nanoparticle drug delivery. Their properties are ideal for drug delivery systems and show promise in
improving controlled release or targeting delivery mechanisms. Natural protein polymer is relatively
cheap, easy to process, and renewable which makes it an attractive material from an economic
perspective. The primary advantages that protein-based nanoparticles have over synthetic materials is
their biodegradability and biocompatibility. Minimizing the host immune response is an important
aspect determining the success of a drug delivery operation. The natural degradation of these protein
polymers reduces accumulation of particle byproduct which is also better for the human health.
This review focused on the properties of protein materials, such as silk fibroin, keratin, and elastin,
and their usage in nanoparticle drug delivery and biomedical applications. There are a variety
of processing methods for protein-based nanoparticles which can tune their resulting properties
for more specific applications. While there are still challenges to overcome, there is an increasing
demand for biocompatible protein nanoparticles in the medical field. To overcome these challenges,
future work involving protein-based nanoparticles must focus on the development of large scale
production techniques that allow these particles to be manufactured in a commercially attractive
manner. Functionalized particles capable of targeting specific areas of the body are also likely to be
developed to limit off-target effects. With the development of new pharmaceuticals, the fabrication
and characteristics of protein nanoparticles must also adapt to provide ideal vehicles for drug delivery.
As these new studies emerge and the functionality of these protein materials is improved, the more
opportunities there will be for effective disease treatment in the future.
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